# A Study to Evaluate the Effect of Mild, Moderate, and Severe Hepatic Impairment on Pharmacokinetics of Sitravatinib

> **NCT04772612** · PHASE1 · COMPLETED · sponsor: **Mirati Therapeutics Inc.** · enrollment: 30 (actual)

## Conditions studied

- Hepatic Impairment

## Interventions

- **DRUG:** sitravatinib

## Key facts

- **NCT ID:** NCT04772612
- **Lead sponsor:** Mirati Therapeutics Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-03-12
- **Primary completion:** 2022-07-13
- **Final completion:** 2023-04-13
- **Target enrollment:** 30 (ACTUAL)
- **Last updated:** 2023-10-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04772612

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04772612, "A Study to Evaluate the Effect of Mild, Moderate, and Severe Hepatic Impairment on Pharmacokinetics of Sitravatinib". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT04772612. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*